



PRESS RELEASE

## Moberg Pharma to participate at EADV and CPHI

**STOCKHOLM, September 28, 2026.** Moberg Pharma AB (OMX: MOB) will participate at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, September 30–October 3, and the Convention on Pharmaceutical Ingredients (CPHI) in Milan, October 6–8, 2026. The events provide important opportunities to engage with leading dermatology experts, commercial partners and pharmaceutical manufacturers ahead of the broader international rollout of MOB-015.

MOB-015 is a topical terbinafine treatment for onychomycosis. The product is currently approved in 14 countries and is marketed as Terclara® in Sweden and Norway, where it is the market leader. Commercial partnerships are in place across Europe, APAC, Canada and China, providing the platform for a broader international rollout. Together with Karo Healthcare, preparations are underway for launches across multiple markets under the Lamisil® brand.

*"EADV is one of the most important international meetings in dermatology and an excellent opportunity for us to meet with leading experts and partners, while CPHI brings together manufacturers and suppliers from across the global pharmaceutical industry. With preparations for the broader European rollout of MOB-015 progressing, we look forward to productive discussions in both Vienna and Milan,"* says Anna Ljung, CEO of Moberg Pharma.

**For additional information, please contact:**

Anna Ljung, CEO, Phone: +46 8 522 307 01, e-mail: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

**About this information**

The information was released for public distribution through the contact named above, on September 28<sup>th</sup>, 2026, at 8:00 am CEST.

**About Moberg Pharma, [www.mobergpharma.com](http://www.mobergpharma.com)**

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 14 countries. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. MOB-015 is sold in Sweden, Norway and Israel under the brand name Terclara®. Moberg Pharma has agreements with commercial partners in place in various regions including Europe, APAC, Canada and China. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).